PaulB.EckburgMD

Infectious Disease • Mountain View, CA

Infectious Diseases at Stanford University and Anti-Infective Drug Development in Industry

Join to view full profile

Dr. Eckburg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Eckburg's full profile

Already have an account?

Office
1785 Woodhaven Pl
Mountain View, CA 94041
Is this information wrong?

Education & Training

Stanford Health Care2004
Stanford Health Care-Sponsored Stanford UniversityFellowship, Infectious Disease, 2000 - 2002
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1996 - 1999
Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1996 - 1997
Rush Medical College of Rush University Medical CenterClass of 1996

Certifications & Licensure

CA State Medical License 1997 - 2025
HI State Medical License 1999 - 1999

Clinical Trials

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections Start of enrollment: 2007 Mar 01
Completed
Phase 3
Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections Start of enrollment: 2007 Feb 01
Completed
Phase 3
Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia Start of enrollment: 2007 Jul 01
Completed
Phase 3
Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia Start of enrollment: 2008 Jan 01
Completed
Phase 3
Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital Start of enrollment: 2011 Apr 01
Completed
Phase 4
A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia Start of enrollment: 2011 Dec 01
Completed
Phase 3
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections Start of enrollment: 2011 Dec 01
Completed
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

6 citations
Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia.
Antoni Torres, Lynne Garrity-Ryan, Courtney Kirsch, Judith N. Steenbergen, Paul B. Eckburg, Anita Das, Marla Curran, Amy Manley, Evan Tzanis, Paul C. McGovern> ;International Journal of Infectious Diseases. 2021 Jan 20
73 citations
Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase...
Keith S Kaye, Louis B. Rice, Aaron Dane, Viktor Stus, Olexiy S. Sagan, Elena Fedosiuk, Anita Das, David Skarinsky, Paul B. Eckburg, Evelyn J. Ellis-Grosse> ;Clinical Infectious Diseases. 2019 Nov 27
56 citations
Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, ...
William O'Riordan, Carrie Cardenas, Elliot Shin, Alissa Sirbu, Lynne Garrity-Ryan, Anita Das, Paul B. Eckburg, Amy Manley, Judith N. Steenbergen, Evan Tzanis, Paul C. ...> ;The Lancet. Infectious Diseases. 2019 Oct 1
17 citations
Safety, Pharmacokinetics, and Food Effect of Tebipenem Pivoxil Hydrobromide after Single and Multiple Ascending Oral Doses in Healthy Adult Subjects.
Paul B. Eckburg, Akash Jain, Susannah M. Walpole, Grayson Moore, Luke Utley, Erika Manyak, Aaron Dane, David Melnick> ;Antimicrobial Agents and Chemotherapy. 2019 Aug 23
23 citations
Omadacycline for Acute Bacterial Skin and Skin Structure Infections.
Fredrick M. Abrahamian, George Sakoulas, Evan Tzanis, Amy Manley, Judith N. Steenbergen, Anita Das, Paul B. Eckburg, Paul C. McGovern> ;Clinical Infectious Diseases. 2019 Aug 1
30 citations
Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combin...
Paul B. Eckburg, Troy Lister, Susannah M. Walpole, Tim Keutzer, Luke Utley, John Tomayko, Ellen Kopp, Nicholas Farinola, Scott Coleman> ;Antimicrobial Agents and Chemotherapy. 2019 Aug 23
126 citations
Omadacycline for Community-Acquired Bacterial Pneumonia
Roman Stets, Monica Popescu, Joven Gonong, Ismail Mitha, William Nseir, Andrzej Madej, Courtney Kirsch, Anita Das, Lynne Garrity-Ryan, Judith N. Steenbergen, Amy Manle...> ;The New England Journal of Medicine. 2019 Feb 6
102 citations
Omadacycline for Acute Bacterial Skin and Skin-Structure Infections
William O'Riordan, Sinikka Green, J Scott Overcash, Ivan Puljiz, Symeon Metallidis, J Gardovskis, Lynne Garrity-Ryan, Anita Das, Evan Tzanis, Paul B. Eckburg, Amy Manl...> ;The New England Journal of Medicine. 2019 Feb 6
6 citations
Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
Thomas M. File, Paul B. Eckburg, George H. Talbot, Lily Llorens, H. David Friedland> ;International Journal of Antimicrobial Agents. 2017 Aug 1
21 citations
Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects.
Paul B. Eckburg, Yigong Ge, Barry Hafkin> ;Antimicrobial Agents and Chemotherapy. 2017 Apr 1
8 citations
Efficacy of Ceftaroline Fosamil for Bacteremia Associated With Community-Acquired Bacterial Pneumonia
Alena Jandourek, Alexander Smith, Lily Llorens, Dirk Thye, Paul B. Eckburg, H. David Friedland> ;Hospital Practice. 2014 Feb 1
9 citations
Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials
Andrew F. Shorr, Marin H. Kollef, Paul B. Eckburg, Lily Llorens, H. David Friedland> ;Diagnostic Microbiology and Infectious Disease. 2013 Mar 1
59 citations
CANVAS 1 and 2: Analysis of Clinical Response at Day 3 in Two Phase 3 Trials of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in Treatment of Acute Bacterial Sk...
H. David Friedland, Tanya O'Neal, Donald Biek, Paul B. Eckburg, Douglas R. Rank, Lily Llorens, Alexander Smith, Gary W. Witherell, Joseph B. Laudano, Dirk Thye> ;Antimicrobial Agents and Chemotherapy. 2012 May 1
148 citations
FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia
Donald E. Low, Thomas M. File, Paul B. Eckburg, George H. Talbot, H. David Friedland, Jon Lee, Lily Llorens, Ian A. Critchley, Dirk Thye, Jorge Corral, Eduardo Giugno,...> ;The Journal of Antimicrobial Chemotherapy. 2011 Apr 1
31 citations
Review of ceftaroline fosamil microbiology: integrated FOCUS studies
Ian A. Critchley, Paul B. Eckburg, Alena Jandourek, Donald Biek, H. David Friedland, Dirk Thye> ;The Journal of Antimicrobial Chemotherapy. 2011 Apr 1
162 citations
FOCUS 1: A randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia
Thomas M. File, Donald E. Low, Paul B. Eckburg, George H. Talbot, H. David Friedland, Jon Lee, Lily Llorens, Ian A. Critchley, Dirk Thye, John Pullman, Philip Giordano...> ;The Journal of Antimicrobial Chemotherapy. 2011 Apr 1
163 citations
Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled-Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxon...
Thomas M. File, Donald E. Low, Paul B. Eckburg, George H. Talbot, H. David Friedland, Jon Lee, Lily Llorens, Ian A. Critchley, Dirk Thye> ;Clinical Infectious Diseases. 2010 Dec 15
143 citations
The Role of Microbes in Crohn's Disease
Paul B. Eckburg, David A. Relman> ;Clinical Infectious Diseases. 2007 Jan 15
60 citations
Microarray Detection of Human Parainfluenzavirus 4 Infection Associated with Respiratory Failure in an Immunocompetent Adult
Charles Y. Chiu, Silvi Rouskin, Anita A. Koshy, Anatoly Urisman, Kael F. Fischer, Shigeo Yagi, David P. Schnurr, Paul B. Eckburg, Lucy S. Tompkins, Brian G. Blackburn,...> ;Clinical Infectious Diseases. 2006 Oct 15
292 citations
Assembly of the human intestinal microbiota
Les Dethlefsen, Paul B. Eckburg, Elisabeth M. Bik, David A. Relman> ;Trends in Ecology & Evolution. 2006 Sep 1
2913 citations
Metagenomic Analysis of the Human Distal Gut Microbiome
Steven R. Gill, Mihai Pop, Robert T. DeBoy, Paul B. Eckburg, Peter J. Turnbaugh, Buck S. Samuel, Jeffrey I. Gordon, David A. Relman, Claire M. Fraser-Liggett, Karen E....> ;Science. 2006 Jun 2
423 citations
Molecular analysis of the bacterial microbiota in the human stomach.
Elisabeth M Bik, Paul B Eckburg, Steven R Gill, Karen E Nelson, Elizabeth A Purdom, Fritz Francois, Guillermo Perez-Perez, Martin J Blaser, David A Relman> ;Proceedings of the National Academy of Sciences of the United States of America. 2006 Jan 17
131 citations
Rapid quantitative profiling of complex microbial populations
Chana Palmer, Elisabeth M. Bik, Michael B. Eisen, Paul B. Eckburg, Theodore R. Sana, Paul K. Wolber, David A. Relman, Patrick O. Brown> ;Nucleic Acids Research. 2006 Jan 1
5094 citations
Diversity of the human intestinal microbial flora.
Paul B. Eckburg, Elisabeth M. Bik, Charles N. Bernstein, Elizabeth Purdom, Les Dethlefsen, Michael Sargent, Steven R. Gill, Karen E. Nelson, David A. Relman> ;Science. 2005 Jun 10
Monkeypox and medical ethics.
Daniel B. DiGiulio, Paul B. Eckburg> ;The Pediatric Infectious Disease Journal. 2004 May 1
Join now to see all

Press Mentions

Recida Therapeutics Raises $8.5M in Series AFebruary 9th, 2019
Frazier Healthcare Partners Launches Recida Therapeutics to Develop Novel Therapeutics for Serious Antibiotic-Resistant InfectionsFebruary 6th, 2019
UTILITY Receives Qualified Infectious Disease Product Designation from the U.S. FDAMay 21st, 2018
Join now to see all